» Articles » PMID: 35922651

ADAR3 Activates NF-κB Signaling and Promotes Glioblastoma Cell Resistance to Temozolomide

Overview
Journal Sci Rep
Specialty Science
Date 2022 Aug 3
PMID 35922651
Authors
Affiliations
Soon will be listed here.
Abstract

The RNA binding protein ADAR3 is expressed exclusively in the brain and reported to have elevated expression in tumors of patients suffering from glioblastoma compared to adjacent brain tissue. Yet, other studies have indicated that glioblastoma tumors exhibit hemizygous deletions of the genomic region encompassing ADAR3 (10p15.3). As the molecular and cellular consequences of altered ADAR3 expression are largely unknown, here we directly examined the impacts of elevated ADAR3 in a glioblastoma cell line model. Transcriptome-wide sequencing revealed 641 differentially expressed genes between control and ADAR3-expressing U87-MG glioblastoma cells. A vast majority of these genes belong to pathways involved in glioblastoma progression and are regulated by NF-κB signaling. Biochemical and molecular analysis indicated that ADAR3-expressing U87-MG cells exhibit increased NF-κB activation, and treatment with an NF-κB inhibitor abrogated the impacts of ADAR3 on gene expression. Similarly, we found that increased cell survival of ADAR3-expressing cells to temozolomide, the preferred chemotherapeutic for glioblastoma, was due to increased NF-κB activity. Aberrant constitutive NF-κB activation is a common event in glioblastoma and can impact both tumor progression and resistance to treatment. Our results suggest that elevated ADAR3 promotes NF-κB activation and a gene expression program that provides a growth advantage to glioblastoma cells.

Citing Articles

CENPF interaction with PLA2G4A promotes glioma growth by modulating mTORC1 and NF-κB pathways.

Li J, Zhang M, Sun Q, Li X, Du F, Cheng Y Cancer Cell Int. 2025; 25(1):73.

PMID: 40025532 PMC: 11871623. DOI: 10.1186/s12935-025-03700-6.


Comprehensive Mapping of Human dsRNAome Reveals Conservation, Neuronal Enrichment, and Intermolecular Interactions.

Andrews R, Bass B bioRxiv. 2025; .

PMID: 39975386 PMC: 11838218. DOI: 10.1101/2025.01.24.634786.


Emerging Roles and Mechanisms of RNA Modifications in Neurodegenerative Diseases and Glioma.

Kobayashi A, Kitagawa Y, Nasser A, Wakimoto H, Yamada K, Tanaka S Cells. 2024; 13(5.

PMID: 38474421 PMC: 10931090. DOI: 10.3390/cells13050457.


The competitive landscape of the dsRNA world.

Cottrell K, Andrews R, Bass B Mol Cell. 2023; 84(1):107-119.

PMID: 38118451 PMC: 10843539. DOI: 10.1016/j.molcel.2023.11.033.


The epitranscriptome of high-grade gliomas: a promising therapeutic target with implications from the tumor microenvironment to endogenous retroviruses.

Ramsoomair C, Ceccarelli M, Heiss J, Shah A J Transl Med. 2023; 21(1):893.

PMID: 38071304 PMC: 10709919. DOI: 10.1186/s12967-023-04725-z.


References
1.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

2.
Whiteside S, Epinat J, Rice N, Israel A . I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. EMBO J. 1997; 16(6):1413-26. PMC: 1169738. DOI: 10.1093/emboj/16.6.1413. View

3.
Han L, Diao L, Yu S, Xu X, Li J, Zhang R . The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 2015; 28(4):515-528. PMC: 4605878. DOI: 10.1016/j.ccell.2015.08.013. View

4.
Zhang Y, Wang K, Zhao Z, Sun S, Zhang K, Huang R . ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2. Cancer Cell Int. 2018; 18:196. PMC: 6276233. DOI: 10.1186/s12935-018-0695-8. View

5.
Baune B, Wiede F, Braun A, Golledge J, Arolt V, Koerner H . Cognitive dysfunction in mice deficient for TNF- and its receptors. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(7):1056-64. DOI: 10.1002/ajmg.b.30712. View